AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04492098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MAIT cells
Description: 1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
Study NCT06295367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive PAF brochure describing financial navigation services
Study NCT06295367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive PAF brochure describing financial navigation services
Study NCT06295367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Navigation
Description: Receive CostCOM financial counseling
Study NCT06295367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in a 1 on 1 in-depth interview
Study NCT06295367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06295367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05534906 — intervention group
Intervention type: OTHER
Intervention: Blood & Urine Samples
Description: Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time
Study NCT05534906 — intervention group
Intervention type: OTHER
Intervention: Imaging
Description: MRI \& MRE Scans
Study NCT05175573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA Et Nasal Positive Pressure Mask
Description: Nasal mask with capnography providing continuous positive airway pressure at 10LPM
Study NCT05175573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Oxygen Face Mask
Description: Face mask with capnography providing oxygenation at 10 LPM
Study NCT05242731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSmonitor, a self-management/education program with e-health interventions
Description: A self-management/education program with e-health interventions
Study NCT05242731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video calling program Better-close
Description: Video calling program.
Study NCT05242731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Researchmanager program
Description: Case Report Form, Datamanagement program
Study NCT06400173 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive screening
Description: The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.
Study NCT06400173 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audiological Assessment
Description: Four audiological tests are included in the audiological assessment~1. Tympanometry to assss the middle ear status~2. Pure-tone audiometry with headphone to evaluate the hearing thresholds~3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise~4. The hAVICOP questionnaire to assess the hearing-related quality of life
Study NCT05774925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study NCT05378997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCP-25 gel 0.86 mg/ml or placebo gel
Description: TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Study NCT05378997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCP-25 gel 2.9 mg/ml or placebo gel
Description: TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Study NCT05378997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCP-25 gel 8.6 mg/ml or placebo gel
Description: TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Study NCT04845321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-9945
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Study NCT04845321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VNRX-9945
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Study NCT06118983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-TRANSFER-HF
Description: I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US.
Study NCT06052163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide
Description: Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
Study NCT06052163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo has no active properties and is taken orally.
Study NCT05992870 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment.
Study NCT04856930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imsidolimab
Description: Humanized Monoclonal Antibody
Study NCT04856930 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Placebo
Study NCT04550104 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
Study NCT04550104 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
Study NCT04550104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Tablet [Lynparza]
Description: Oral tablet
Study NCT04550104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1390
Description: Oral tablet
Study NCT04550104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Oral Tablet
Study NCT04550104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral Tablet
Study NCT04550104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg iv infusion
Study NCT04550104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: 1500mg iv infusion
Study NCT05111444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion
Study NCT05111444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pyrotinib
Description: 320mg as continuous oral once daily on every 21 days
Study NCT05111444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
Study NCT05233306 — intervention group
Intervention type: DEVICE
Intervention: MRI scanner (7 Tesla)
Description: MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
Study NCT05111444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
Study NCT05111444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
Study NCT05111444 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: S-1
Description: Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
Study NCT04704830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: Adjuvanted malaria vaccine
Study NCT04704830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator
Study NCT04704830 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine or Hepatitis A vaccine
Description: Placebo Comparator
Study NCT05259813 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWCAR029 (Relmacabtagene Autoleucel)
Description: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hcl 1000Mg Tab
Description: Agent used to modify insulin sensitivity
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminohippurate Sodium 20 % Injection
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aminohippurate Sodium 20 % Injection
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aminohippurate Sodium 20 % Injection
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol 300 Mg/mL Injectable Solution
Description: Diagnostic aid/agent used to measure glomerular filtration rate
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol 300 Mg/mL Injectable Solution
Description: Diagnostic aid/agent used to measure glomerular filtration rate
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol 300 Mg/mL Injectable Solution
Description: Diagnostic aid/agent used to measure glomerular filtration rate
Study NCT05065372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
Study NCT06064942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Narrative Therapy (MFNT)
Description: MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
Study NCT06064942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School services for families of children with ADHD
Description: Selected school social personnel will deliver services as usual for the control group.
Study NCT05043571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
Study NCT04974554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT
Description: FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.
Study NCT04974554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Family Support
Description: Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
Study NCT04776473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open treatment
Description: Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
Study NCT04776473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Closed treatment
Description: Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
Study NCT06385730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant anti-PD-1
Description: PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
Study NCT06385730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant anti-PD-1 with LDRT
Description: Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
Study NCT06512012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga and exercise
Description: Technology-Assisted Yoga and Exercise Intervention during 6 months
Study NCT04944654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIKTARVY 50Mg-200Mg-25Mg Tablet
Description: Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
Study NCT05857527 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Custom EMG triggered Soterix taVNS stimulation with CIMT therapy
Description: Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session.
Study NCT04870411 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
Study NCT05429788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose RLS103
Description: 3 mg CBD inhaled powder administered before public speaking challenge
Study NCT05429788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose RLS103
Description: 6 mg CBD inhaled powder administered before public speaking challenge
Study NCT05429788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo inhaled dry powder
Description: placebo inhaled powder administered before public speaking challenge
Study NCT06082388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of atropine and isoprenaline
Description: Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
Study NCT05020171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group of strength training
Description: 2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
Study NCT05020171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group of physiotherapy not focus on strength training
Description: 2x a week during 5 weeks, active physical therapy treatment based on movement
Study NCT05551715 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Software development for individualized refractive surgery
Description: Software development for individualized refractive surgery
Study NCT06209554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser
Description: diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
Study NCT05795686 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of program AVanCer
Description: Evaluation of program AVanCer with quantitative and qualitative approaches
Study NCT05382247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonography
Description: Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone.
Study NCT05442151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PET/CT ([F-18]FAPI-74)
Description: PET/CT using \[18F\] FAPI-74 injection
Study NCT05487898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling wheelchair
Description: Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
Study NCT05280028 — intervention group
Intervention type: DRUG
Intervention: Tibolone 2.5 mg
Description: Tibolone 2.5 mg per day
Study NCT05280028 — intervention group
Intervention type: DRUG
Intervention: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg
Description: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
Study NCT06229106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symfony IOL
Description: The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
Study NCT06229106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivity IOL
Description: The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
Study NCT06443918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Just-in-Time Adaptive Intervention for Child and Family Mental Health
Description: Families in the intervention group will download an app on their smartphones. The app will deliver psychoeducational modules and family-based homework activities. It will include a component where AI is used to assess the quality of family-based interactions and provide in-the-moment feedback and coaching to guide the family interaction.
Study NCT06031649 — intervention group
Intervention type: DEVICE
Intervention: MyotonPRO device
Description: It is a valid and reliable device for measuring the muscular mechanical properties